Sign up Australia
Proactive Investors - Run By Investors For Investors

Osprey Medical attracts $10 million from investment manager Allan Gray

The company is aiming to raise a further $10.5 million from a non-renounceable entitlement offer.
Osprey has achieved consistent quarterly unit sales growth

Osprey Medical Inc (ASX:OSP) has raised $10 million via a private placement to Allan Gray, a leading South Africa based investment management firm.

The company has issued about 64 million CHESS Depositary Interests (CDIs) (representing about 32 million Osprey shares) to Allan Gray at 15.5 cents per CDI.


In addition to the placement, Osprey is offering existing holders of CDIs in Australia, New Zealand, Hong Kong and Singapore the opportunity to participate in a pro-rata non-renounceable entitlement offer.

Eligible holders will have the opportunity to subscribe for one new CDI for every five CDIs held by them at an offer price of 15.5 cents per CDI.

Osprey is aiming to raise a maximum of about $10.5 million from the entitlement offer.


Osprey is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures.

The company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design.

Quarterly DyeVert sales

In July 2018, Osprey revealed three contracts with leading GPOs (group purchasing organisation) in the US covering around 10% of the addressable market for Osprey’s DyeVert products.

GPOs represent some of the largest networks of hospitals and healthcare providers in the US.

In October 2018, Osprey received an award from Premier, Inc., one of the largest GPOs in the US.

View full OSP profile View Profile

Osprey Medical Ltd Timeline

Related Articles

July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use